With expertise across sectors spanning pharmaceutical, medical devices and crop sciences, Mishcon de Reya LLP provides both contentious and non-contentious assistance for clients ranging from emerging companies to multinationals. Patrick Farrant leads the life sciences group and frequently advises on mandates such as IP licences, R&D agreements and spin-outs. IP disputes specialist David Rose is geared to handle trade mark and patent cases in the UK and across Europe. Gayle Curry, who joined the team following the firm���s January 2023 merger with Taylor Vinters, is notably strong on matters connected to digital health.
Legal 500 Editorial commentary
Key clients
- AccuRx
- Binx Health Limited
- Brookfield
- Centauri Therapeutics
- DIOSynVax
- Dama Health
- Dr Reddy Laboratories
- Endomagnetics Limited
- LoQus23
- Luye Pharma
- MatchBio Limited
- Maxion
- Medoron
- Mestag Therapeutics
- Microbiotica Limited
- Nanna Therapeutics
- Nucleome Therapeutics
- Osstec Ltd
- PetMedix
- PharmEnable
- Quell Therapeutics
- RQ Bio
- RSC
- RxCelerate
- Sania Therapeutics
- Sanofi
- T-Therapeutics
- ViaNutis (previously SomaServe)
- Zentiva Pharma
Work highlights
- Advised RQ Bio on its strategic collaboration with AbCellera to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio.
- Acting for Dr Reddy's Laboratories in a significant follow on cross-undertaking in damages claim against Warner-Lambert relating to pregabalin.
- Acted for Maxion Therapeutics Limited on an investment of £12,000,000 from various investors including LifeArc, Monograph Capital Partners I LP, and BGF Investment Management Limited.
Practice head
The lawyer(s) leading their teams.
Patrick Farrant